Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Amengual, O.
Right arrow Articles by Hughes, G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amengual, O.
Right arrow Articles by Hughes, G. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The British Journal of Rheumatology, Vol 36, 964-968, Copyright © 1997 by British Society for Rheumatology

ORIGINAL PAPERS

Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome

O Amengual, T Atsumi, MA Khamashta, F Tinahones and GR Hughes
Lupus/Arthritis Research Unit, The Rayne Institute, St Thomas' Hospital, London.

The prevalence and clinical significance of anti-oxidized low-density lipoprotein antibodies (anti-ox-LDL) were evaluated in patients with the antiphospholipid syndrome (APS). Anti-ox-LDL were measured in the sera of 107 patients with APS (64 primary APS, 43 secondary to systemic lupus erythematosus) by enzyme-linked immunosorbent assay (ELISA) utilizing malondialdehyde (MDA)-modified LDL as antigen. In the same patients, anticardiolipin antibodies (aCL) and anti-beta2-glycoprotein I antibodies (anti-beta2GPI) were also measured. A positive titre of anti-ox-LDL was detected in 22% of patients, but only in 6% of control subjects (chi2 = 12, P = 0.0005). Levels of anti-ox-LDL were higher in patients with arterial thrombosis (n = 58) than in those without (n = 49) (P = 0.0001). Anti-ox-LDL levels correlated weakly with those of aCL (r = 0.196, P = 0.043), but not with those of anti-beta2GPI (r = 0.076). Our findings suggest that elevated levels of anti-ox-LDL may represent another potential marker of APS, particularly of patients prone to arterial thrombosis.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
A.W.S. de Souza, N.P. Silva, J.F. de Carvalho, V. D'Almeida, M.A.E. Noguti, and E.I. Sato
Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome
Lupus, October 1, 2007; 16(10): 782 - 787.
[Abstract] [PDF]

Home page
 ANGIOLOGYHome page
T. Akimoto, S. Kobayashi, N. Tamura, T. Ohsawa, T. Kawano, M. Tanaka, and H. Hashimoto
Risk Factors for Recurrent Thrombosis: Prospective Study of a Cohort of Japanese Systemic Lupus Erythematosus
Angiology, September 1, 2005; 56(5): 601 - 609.
[Abstract] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
M. A. Ozturk, I. C. Haznedaroglu, M. Turgut, and H. Goker
Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia
Clinical and Applied Thrombosis/Hemostasis, April 1, 2004; 10(2): 89 - 126.
[Abstract] [PDF]

Home page
 Circ. Res.Home page
J. H. Rand
Molecular Pathogenesis of the Antiphospholipid Syndrome
Circ. Res., January 11, 2002; 90(1): 29 - 37.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
G Hayem, P Nicaise-Roland, E Palazzo, M de Bandt, F Tubach, M Weber, and O Meyer
Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome
Lupus, May 1, 2001; 10(5): 346 - 351.
[Abstract] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. L. Herrick, K. J. Illingworth, S. Hollis, J. M. Gomez-Zumaquero, and F. J. Tinahones
Antibodies against oxidized low-density lipoproteins in systemic sclerosis
Rheumatology, April 1, 2001; 40(4): 401 - 405.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
Y S Haviv
Association of anticardiolipin antibodies with vascular injury: possible mechanisms
Postgrad. Med. J., October 1, 2000; 76(900): 625 - 628.
[Full Text]

Home page
 LupusHome page
R Hilker, A Thiel, C Geisen, and J Rudolf
Cerebral blood flow and glucose metabolism in multi-infarct-dementia related to primary antiphospholipid antibody syndrome
Lupus, May 1, 2000; 9(4): 311 - 316.
[Abstract] [PDF]

Home page
 LupusHome page
G R. Hughes
Immunology, lupus and atheroma
Lupus, March 1, 2000; 9(3): 159 - 160.
[PDF]

Home page
 LupusHome page
O Vaarala
Antibodies to oxidised LDL
Lupus, March 1, 2000; 9(3): 202 - 205.
[Abstract] [PDF]

Home page
 LupusHome page
F I Romero, M A Khamashta, and G R. Hughes
Lipoprotein(a) oxidation and autoantibodies: a new path in atherothrombosis
Lupus, March 1, 2000; 9(3): 206 - 209.
[Abstract] [PDF]

Home page
 NeurologyHome page
D. Tanne, L. D'Olhaberriague, L. R. Schultz, L. Salowich-Palm, K. L. Sawaya, and S. R. Levine
Anticardiolipin antibodies and their associations with cerebrovascular risk factors
Neurology, April 1, 1999; 52(7): 1368 - 1368.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
D. Tanne, D. A. Triplett, and S. R. Levine
Antiphospholipid-Protein Antibodies and Ischemic Stroke : Not Just Cardiolipin Any More
Stroke, September 1, 1998; 29(9): 1755 - 1758.
[Full Text] [PDF]

Home page
 LupusHome page
J-C. Piette
Review : Towards improved criteria for the antiphospholipid syndrome
Lupus, January 1, 1998; 7(2_suppl): S149 - S157.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.